secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001628280-22-021061
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q3 FY2022 revenue $32.4M, net loss $72.0M; pipeline progresses
------------------------------------------------------------------------

- Q3 FY2022 revenue $32.4M (down 29% YoY); net loss $72.0M ($0.68 loss per share) vs $29.9M loss prior year.
- Total cash & investments $582.4M, down from $613.4M at Sept 2021; operating loss $72.9M.
- Phase 2 fazirsiran: fibrosis regression in 58%, median 83% reduction in Z-AAT accumulation in liver.
- Initiated Phase 1/2a for ARO-MUC5AC and ARO-RAGE; Phase 2 GATEWAY for ARO-ANG3 in HoFH started.
- Hired Tracie Oliver as CCO; promoted Patrick O'Brien to COO; formed JV Visirna Therapeutics with Vivo Capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828022021061/0001628280-22-021061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828022021061/arwr-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-021061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer